About Us

A First in Class Product that can act as a “Platform” Applicable to Multiple Diseases

ImmCelz® is Optimized Stem Cell
Mediated Immune Modulation

  • Replication of stem cell-immune interaction in vitro
  • Optimized stem cells (universal donor) are cultured with patient’s own immune cells or conditioned by exposure to factors made by the universal donor cells
  • Culture occurs in optimized conditions
  • The stem cells “reprogram” donor immune cells to endow regenerative activity
  • Donor cells are then harvested from the co-culture and injected back into patient.

ImmCelz® Production

Graphic 1

Some Basic Properties ImmCelz® Product

Immune Modulation Innate

Immune Modulation Adaptive

Angiogenic

Regenerative

Suppression of Innate Immunity: ImmCelz® Inhibits
TNF-alpha Production from Activated Macrophages

Allogeneic peripheral blood mononuclear cells (PBMC) were incubated with umbilical cord mesenchymal stem cells for 48 hours in a transwell chamber and subsequently added to lipopolysaccharide stimulated macrophages at a 1:1 ratio. Assessment of TNF-alpha was performed by ELISA at the indicated time points

Time Point 1

Suppression of Th17
Pathological Adaptive Immunity

Allogeneic peripheral blood mononuclear cells (PBMC) were incubated with umbilical cord mesenchymal stem cells for 48 hours in a transwell chamber and subsequently added to lipopolysaccharide stimulated macrophages at a 1:1 ratio. Assessment of TNF-alpha was performed by ELISA at the indicated time points

Graphic 3

ImmCelz® Stimulates Angiogenesis

Allogeneic peripheral blood mononuclear cells (PBMC) were incubated with umbilical cord mesenchymal stem cells for 48 hours in a transwell chamber or only in conditioned media and subsequently added to human umbilical vein endothelial cells (HUVEC) at the indicated ratio. Proliferation was assessed by tritiated thymidine incorporation.

Graphic 4

ImmCelz® Stimulates Regenerative
Cytokine VEGF

Allogeneic peripheral blood mononuclear cells (PBMC) were incubated with umbilical cord mesenchymal stem cells for 48 hours in a transwell chamber or only in conditioned media and subsequently added fibroblasts at the indicated ratio. Cytokine expression was determined by ELSIA

Graphic 5

ImmCelz® Activity in vivo
Associated with Tolerogenic Loop

Graphic 6
  • Immunological tolerance is essential for prevention of autoimmune diseases and continuation of pregnancy (paradox of the fetal allograft)
  • Tolerance is usurped by cancer to escape immunological destruction
  • Maintenance of immunological tolerance is an active process that can be blocked by deletion or inactivation of certain immunological elements
  • ImmCelz® Founder Dr Thomas Ichim published in 2003 the Tolerogenic Loop hypothesis of immune tolerance
  • ImmCelz® induces tolerance by stimulating the Tolerogenic Loop
ImmCelz© 2021 – Creative Medical Technology Holdings, Inc. All rights reserved. ImmCelz® and the ImmCelz® logos are trademarks of Creative Medical Technology Holdings, Inc

Site Links

About

Indications